Clinicopathological characteristics and treatment options of the new grade 3 neuroendocrine tumor subgroup (NETs G3)

#3456

Introduction: NET G3 is a new subgroup of well-differentiated NENs. The impact of morphological characteristics on clinical course and treatment tactics is still questionable.

Aim(s): The objective of our study was to assess somatostatin receptors status (SSTR) in NETs G3 and to evaluate clinicopathological factor (SSTR-2A/5, Ki67, stage, primary site) impact on overall survival (OS) and progression free survival (PFS).

Materials and methods: Our study included 75 pts with NETs G3 of various origins (median Ki67 30.0%, range 23 – 65%): Gastroenteropancreatic (GEP, 54.7%), lungs (24.5%), others (18.9%). 68.8% of pts were stage 4 at the diagnosis and received somatostatin analogues (SA) +/- chemotherapy (ChT). Analysis of OS, PFS and association between clinicopathological factors was performed by Kaplan-Meier method, Cox Proportional-Hazard Model.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Chemeris G, Yemelyanova G, Markovich A,

Keywords: NET G3, SSTR, ki67, somatostatin analogues,